Infant Bacterial Financials
| IBT-B Stock | SEK 50.60 0.80 1.56% |
Infant |
Understanding current and past Infant Bacterial Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Infant Bacterial's financial statements are interrelated, with each one affecting the others. For example, an increase in Infant Bacterial's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Infant Bacterial's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Infant Bacterial Therapeutics. Check Infant Bacterial's Beneish M Score to see the likelihood of Infant Bacterial's management manipulating its earnings.
Infant Bacterial Stock Summary
Infant Bacterial competes with BioGaia AB, Cantargia, XSpray Pharma, and Immunovia Publ. Infant Bacterial Therapeutics AB , a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company was founded in 2013 and is based in Stockholm, Sweden. Infant Bacterial is traded on Stockholm Stock Exchange in Sweden.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0008015259 |
| Business Address | Bryggargatan 10, Stockholm, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.ibtherapeutics.com |
| Phone | 46 7 62 19 37 38 |
| Currency | SEK - Swedish Kronor |
You should never invest in Infant Bacterial without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Infant Stock, because this is throwing your money away. Analyzing the key information contained in Infant Bacterial's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Infant Bacterial Key Financial Ratios
There are many critical financial ratios that Infant Bacterial's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Infant Bacterial reports annually and quarterly.| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Target Price | 300.0 | |||
| Beta | 1.01 |
Infant Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Infant Bacterial's current stock value. Our valuation model uses many indicators to compare Infant Bacterial value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Infant Bacterial competition to find correlations between indicators driving Infant Bacterial's intrinsic value. More Info.Infant Bacterial Therapeutics is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Infant Bacterial's earnings, one of the primary drivers of an investment's value.Infant Bacterial Systematic Risk
Infant Bacterial's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Infant Bacterial volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Infant Bacterial correlated with the market. If Beta is less than 0 Infant Bacterial generally moves in the opposite direction as compared to the market. If Infant Bacterial Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Infant Bacterial is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Infant Bacterial is generally in the same direction as the market. If Beta > 1 Infant Bacterial moves generally in the same direction as, but more than the movement of the benchmark.
Infant Bacterial January 10, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Infant Bacterial help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Infant Bacterial Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Infant Bacterial Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Infant Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Infant Bacterial's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.25 | |||
| Information Ratio | 0.1388 | |||
| Maximum Drawdown | 45.79 | |||
| Value At Risk | (5.77) | |||
| Potential Upside | 9.77 |
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.